LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global liver disease treatment market is expected to grow at a CAGR of more than 11% during the forecast period.
This research report titled ‘Global Liver Disease Treatment Market 2017-2021’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.
The liver is the largest organ of the body and can completely recover from damage. However, the continuous strain on the liver, or when treatment is delayed for a prolonged period, can lead to severe damage to the liver and can even be fatal. Viral hepatitis is one of the major liver diseases affecting a large number of people across the globe. This is caused by viral infections and spread through contaminated food and water. Poor sanitation facilities in developing countries such as India and China has led to a higher prevalence of the disease in these countries. There has been a rise in healthcare investment in these countries. Also, various government and non-government organizations such as the World Health Organization (WHO) are investing significantly in creating awareness about liver diseases, and this is expected to lead to market growth during the forecast period.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Technavio’s healthcare and life science research analysts categorize the global liver disease treatment market into the following segments by drug class. They are:
- Anti-viral
- Corticosteroids
- Vaccines
- Others
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
The top three drug class segments of the global liver disease treatment market are discussed below:
Anti-viral
Anti-viral drugs are specifically used for viral infections. Antiviral drugs do not destroy the target pathogens. Instead, they inhibit their growth. Most of the antiviral drugs available currently are used for the treatment of HIV, hepatitis, herpes, and influenza. Hepatitis, a major liver disease can be both viral and non-viral.
According to Sapna Jha, a lead cardiovascular and metabolic disorders research analyst from Technavio, “Viral hepatitis holds the majority share of the market and is characterized by inflammation of the liver caused by different strains of the hepatitis virus ranging from viral strands A to E. Of these, hepatitis A, B, and C are the most common types of viral infections.”
Corticosteroids
Corticosteroids, also called steroids, are anti-inflammatory medicines used for the treatment of a range of conditions; they reduce swelling, itching, redness, and allergic reactions. Many studies have shown that corticosteroids can be superior to a mixture of antioxidants in improving clinical parameters and liver histology.
“Corticosteroids hold the majority share of the global liver disease treatment market. This is because numerous therapies involved for the treatment of liver diseases include corticosteroids as a major drug class. Corticosteroids find huge application in middle- and low-income countries majorly due to their low prices,” adds Sapna.
Vaccines
Vaccines are biological preparations that provide immunity to a subject against pathogens. Vaccination is the process of stimulating the immune response in an individual. Vaccines are made of inactive, partially dead or dead viruses that are used to stimulate the immune system against pathogenic viruses and produce antibodies against them.
Factors such as rising awareness about hepatitis infection and mandatory immunization program for the same have led to the high growth of the hepatitis vaccine market. The CDC recommends that the first dose of a hepatitis vaccine must be given to a child between the age 12-23 months. Then a booster shot must be given after 6-18 months. The vaccination must also be given to adults.
The top vendors highlighted by Technavio’s research analysts in this report are:
- F. Hoffmann-la Roche
- Gilead
- GlaxoSmithKline
- Merck
Browse Related Reports:
- Global Celiac Disease Drugs Market 2017-2021
- Global Overactive Bladder Therapeutics Market 2017-2021
- Global Vasculitis Treatment Market 2017-2021
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
